Form 4: AtriCure Director Sells Shares in Pre-Planned Trade

AtriCure Director Regina E. Groves sold 2,452 shares of common stock for approximately $90,290 through a pre-arranged trading plan.

Summary

• Regina E. Groves, a Director of AtriCure, Inc. (ATRC), reported a sale of common stock.
• The transaction involved the disposition of 2,452 shares of AtriCure Common Stock.
• The sale occurred on August 6, 2025, at a weighted average price of $36.82 per share.
• The total value of the shares sold was approximately $90,290.64.
• Following this transaction, Ms. Groves beneficially owns 33,715 shares of AtriCure Common Stock.
• The transaction was executed pursuant to a Rule 10b5-1(c) pre-arranged trading plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While an insider sale can be perceived negatively, the fact that it's a pre-planned 10b5-1 transaction mitigates concerns that it's based on new, adverse information. It's a routine part of an insider's financial planning.

Positives

• The transaction was conducted under a Rule 10b5-1(c) plan, indicating a pre-scheduled sale rather than a reaction to new, non-public information, which can mitigate negative interpretations of insider selling.

Negatives

• A director's sale of shares, even if pre-planned, can sometimes be perceived negatively by the market as it reduces insider ownership and may signal a lack of confidence, although this is not necessarily the case with 10b5-1 plans.

Industry Context

This filing is a routine disclosure of an insider stock transaction within the medical device industry. Such transactions are common and often pre-scheduled, providing limited direct insight into broader industry trends or competitive dynamics.

Management Changes

Related Party Transactions

• The sale of shares by Director Regina E. Groves to the open market constitutes a related party transaction, as it involves a company insider.

Stakeholder Impact

• Shareholders: The sale reduces the director's direct ownership stake, which could be interpreted by some as a slight negative, though the pre-planned nature (10b5-1) typically lessens this impact.
• Employees, Customers, Suppliers, Creditors: No direct impact is indicated by this specific filing.

Key Dates

Recommendation

The filing details a routine, pre-planned insider sale under a 10b5-1 plan. While any insider sale can be viewed with caution, the pre-scheduled nature suggests it's not based on new, material non-public information. This transaction alone does not provide sufficient new information to warrant a change in investment recommendation for AtriCure, Inc. The core business fundamentals and broader market conditions remain the primary drivers for investment decisions.

Keywords

AtriCure, ATRC, Insider Trading, Form 4, Director Sale, Stock Transaction, 10b5-1 Plan, Medical Devices